Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.
Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L.
Saura C, et al. Among authors: nag sm.
Oncologist. 2013;18(7):787-94. doi: 10.1634/theoncologist.2013-0075. Epub 2013 Jul 12.
Oncologist. 2013.
PMID: 23853246
Free PMC article.
Clinical Trial.